WO2008154395A1 - Prolonged effect disinfectant cleanser - Google Patents

Abstract

The present invention relates to cleanser compositions, and their uses, wherein the cleanser compositions comprise one or more cationic antiseptic agents, a film-forming cationic emulsifying agent, a dispersing auxiliary solvent, a solvent system, and optionally an alkanediol.

Description

070050.3606

IR 2196, 2403

PROLONGED EFFECT DISINFECTANT CLEANSER

PRIORITY INFORMATION

This application claims priority to United States Provisional Application Serial No. 60/942,610, filed June 7, 2007, which is incorporated by reference in its entirety herein.

GRANT INFORMATION Not applicable.

1. INTRODUCTION

The present invention provides for cleansers, and use thereof, which provide enhanced and persistent antimicrobial activity.

2. BACKGROUND OF THE INVENTION "Skin disinfectants (or cleansers)" are routinely used in professional and non-professional contexts to rapidly kill microbes. A physician has a need to disinfect his or her skin both before and after examining a patient. Prior to the

NY02:625743.2 U /0050.3606

IR 2196, 2403 performance of an invasive medical procedure, the skin of the subject must be properly cleaned to avoid post-procedure infections. In the general public, there is an awareness that the spread of infectious diseases can occur by first coming in physical contact with a source of infection - for example touching a contaminated object, and then touching one's eye. To address these needs, a number of different topical disinfectants have been made available.

For example, a number of skin disinfectants have been developed that use alcohol as the primary antimicrobial agent. Alcohol-based skin disinfectants which are known in the art include the following. International Patent Application Publ. No. WO 03/034994 by Modak et al. for "Gentle- Acting Skin Disinfectants and Hydroalcoholic Gel Formulations" discloses compositions comprising antimicrobial agents and octoxyglycerin.

United States Patent No. 6,107, 261 by Taylor et al., issued August 22, 2000, and its continuations-in-part, United States Patent No. 6,204,230 by Taylor et al., issued March 20, 2001 and United States Patent No. 6,136,771 by Taylor et al., issued October 24, 2000, disclose antibacterial compositions which contain an antibacterial agent at a percent saturation of at least 50 percent. The compositions further comprise, as solubility promoters, a surfactant and a hydric solvent, which may be an alcohol. United States Patent No. 5,776,430 by Osborne et al., issued July 7,

1998, discloses a topical antimicrobial cleaner containing about 0.65 -0.85 percent chlorhexidine and about 50-60 percent denatured alcohol, which is scrubbed onto and then rinsed off the skin.

NY02625743 2 070050.3606

IR 2196, 2403 European Patent Application 0604 848 discloses a gel comprising an antimicrobial agent, 40-90 percent by weight of an alcohol, and a polymer and thickening agent.

United States Patent No. 4,956,170 by Lee, issued September 11, 1990 relates to a high alcohol content antimicrobial gel composition which comprises various emollients and a humectant to protect the skin from the drying effects of the alcohol. In alcohol formulations, higher levels of alcohol are needed to provide instant kill against sensitive as well as resistant strains of bacteria.

Certain formulations virtually omit alcohol as a primary antimicrobial agent, such as, for example, the skin sanitizing compositions disclosed in United States Patent No. 6,187,327 by Stack, issued February 13, 2001, which comprises triclosan (2,4,4'-trichloro-2'-hydroxydiphenyl ether; concentration 0.1-0.35 weight percent) in a topical lotion comprised of a surfactant phase and a wax phase, which purportedly provides antimicrobial protection for 3-4 hours after application. The composition prepared according to the claims of United States Patent No. 6,187,327 further comprises chlorhexidine digluconate.

Examples of other disclosures relating to skin disinfectants include the following.

United States Patent No. 6,846,846 by Modak et al. relates to "Gentle- Acting Skin Disinfectants" which comprise octoxyglcerine and an additional antimicrobial agent.

United States Patent Application Publication No. 20050048139 by Modak et al. relates to "Zinc Salt Compositions For The Prevention of Dermal And Mucosal Irritation."

NY02:625743.2 070050.3606

IR 2196, 2403 United States Patent Application Publication No. 20050019431 by

Modak et al. relates to "Antimicrobial Compositions Containing Synergistic Combinations Of Quaternary Ammonium Compounds And Essential Oils And/Or Constituents Thereof." United States Patent No. 5,965,610 by Modak et al., issued October 12,

1999, teaches skin cleaning compositions comprising antimicrobial agents and zinc salts, where zinc salts have a soothing effect on the skin. The claimed subject matter includes formulations comprising a gel formed between zinc gluconate, chlorhexidine gluconate and a solvent, to which various thickening agents, emulsifying agents and/or emollients may be added.

United States Patent No. 5,985,918 by Modak et al., issued November 16, 1999, relates to "Zinc-Based Anti-Irritant Creams".

United States Patent No. 5,705,532 by Modak et al., issued January 6, 1998, relates to "Triple Antimicrobial Compositions" comprising less than or equal to two percent of a chlorhexidine compound, less than or equal to 0.1 percent of a quaternary ammonium compound, and less than or equal to two percent parachlorometaxylenol.

Cleansers with effective antimicrobial activity are desirable for use in the home, in schools, during travel, and in healthcare settings (to name a few). However, even where a surface is successfully cleaned, exposure to new microbes can quickly negate the benefits of cleansing. A cleanser having persistent residual antimicrobial activity would address this issue and help in preventing the spread of infectious agents.

NY02 62₅743 2 070050.3606

IR 2196, 2403 3. SUMMARY OF THE INVENTION

The present invention relates to cleanser compositions, and their uses, wherein the cleanser compositions comprise one or more cationic antiseptic agents, a film-forming cationic emulsifying agent, a dispersing auxiliary solvent, a solvent system, and optionally an alkanediol. It is based, at least in part, on the discovery that cleanser compositions comprising these components provide residual antimicrobial activity which has, in laboratory testing, proved superior to compositions lacking such formulation.

4. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to cleanser compositions, and their uses, wherein the cleanser compositions comprise one or more cationic antiseptic agents, a film-forming and/or surface-coating cationic emulsifying agent, a dispersing auxiliary solvent, a solvent system, and optionally an alkanediol. Preferred non-limiting embodiments further comprise a non-ionic polymer which serves as a foaming agent. For clarity, and not by way of limitation, the detailed description is divided into the following subsections:

(i) cationic antiseptic agents; (ii) cationic emulsifying agents; (iii) dispersing auxiliary solvents;

(iv) non-ionic polymers; (v) solvent systems; (vi) alkanediol s ; (vii) cleanser compositions; and (viii) methods of use.

NY02:625743.2 5 07 .3

IR 2196, 2403

4.1 CATIONIC ANTISEPTIC AGENTS A "cationic antiseptic agent," as that term is used herein, is a compound having a net positive charge which inhibits the growth of microorganisms. Without being limited by any theory, it is believed that such agents tend to bind or adhere to the surface of the skin.

A first non-limiting example of a cationic antiseptic agent which may be used according to the invention is a biguanide antiseptic, such as, but not limited to, chlorhexidine, as a free base or salt, and polyhexamethylene biguanide. Chlorhexidine salts that may be used according to the invention include but are not limited to the following: chlorhexidine diphosphanilate, chlorhexidine digluconate, chlorhexidine diacetate, chlorhexidine dihydrochloride, chlorhexidine dichloπde, chlorhexidine dihydroiodide, chlorhexidine diperchlorate, chlorhexidine dmitrate, chlorhexidine sulfate, chlorhexidine sulfite, chlorhexidine thiosulfate, chlorhexidine di-acid phosphate, chlorhexidine difluorophosphate, chlorhexidine diformate, chlorhexidine dipropionate, chlorhexidine di-iodobutyrate, chlorhexidine di-n- valerate, chlorhexidine dicaproate, chlorhexidine malonate, chlorhexidine succinate, chlorhexidine malate, chlorhexidine tartrate, chlorhexidine dimonoglycolate, chlorhexidine mono-diglycolate, chlorhexidine dilactate, chlorhexidine di-.alpha.- hydroxyisobutyrate, chlorhexidine diglucoheptonate, chlorhexidine di-isothionate, chlorhexidine dibenzoate, chlorhexidine dicinnamate, chlorhexidine dimandelate, chlorhexidine di-isophthalate, chlorhexidine di-2-hydroxy-napthoate, and chlorhexidine embonate. In specific non-limiting embodiments, the amount of biguanide is between about 0.025 and 2.0 percent, or between about 0.2 and 2.0 percent, or between about 0.2 and 1.0 percent, by weight, of the cleanser composition.

NY02 625743 2 6 070050.3606

IR 2196, 2403 "About," as used herein, means plus or minus twenty percent of the recited value(s).

Also, unless indicated otherwise, percentages referred to herein refer to percent by weight (w/w).

A second non-limiting example of a cationic antiseptic agent which may be used according to the invention is triclosan,. In specific, non-limiting embodiments, the amount of triclosan is between about 0.025 and 2.0 percent, or between about 0.15 and 1.0 percent, by weight, of the cleanser composition.

A third non-limiting example of a cationic antiseptic agent which may be used according to the invention is a quaternary ammonium compound, such as benzethonium chloride or benzalkonium chloride or a combination thereof, in an amount between 0.1 and 0.3 percent by weight of the cleansing composition.

A fourth non-limiting example of a cationic antiseptic agent which may be used according to the invention is a compound of the bispyridine class, such as octenidine dihydrochloride. In specific, non-limiting embodiments of the invention, the amount of octenidine dihydrochloride is between about 0.2 and 2 percent by weight of the cleanser composition.

A fifth non-limiting example of a cationic antiseptic agent which may be used according to the invention is hexetidine. In specific, non-limiting embodiments of the invention, the amount of hexetidine is between about 0.05 and 1.0 percent by weight, or between about 0.1 and 0.3 percent by weight, of the cleanser composition.

4.2 CATIONIC EMULSIFYING AGENTS A "cationic emulsifying agent," as that term is used herein, is a compound comprising a cationic lipophilic portion and a hydrophilic portion. In

NY02:62574₃.2 7 070050.3606

IR 2196, 2403 preferred embodiments, the compound contains a quaternary ammonium cation and is soluble in the solvent system set forth below. In particular embodiments, the compound is a conditioning and self-emulsifying wax. Desirably, the compound is capable of forming a film or coating when applied to a surface, such as the skin and the cationic moiety of the compound can bind and/or adhere to the skin surface.

Non-limiting examples of cationic emulsifying agents which may be used according to the invention include incroquat compounds such as (but not limited to) behenyltrimonium methosulfate in cetearyl alcohol (e.g., incroquat behenyl TMS and incroquat behenyl TMS 50 (Croda Inc., Edison, NJ.)), behenalkonium chloride and cetyl alcohol (e.g., Incroquat B-65 (Croda Inc., Edison, NJ.)), behenamido propyl ethyl dimonium ethosulfate and stearyl alcohol (Incroquat BES-35 S (Croda Inc., Edison, NJ.)), steralkonium chloride and cetearyl alcohol and PEG-40 Castor oil (e.g., Incroquat CR concentrate (Croda Inc., Edison, NJ.)), Incroquat CTC-30 (Croda Inc., Edison, NJ. ), Incroquat DBM-90 (Croda Inc. , Edison, NJ.), Incroquat O-50 (Croda Inc., Edison, NJ.), Incroquat S-DQ-25 (Croda Inc., Edison, NJ.), Incroquat BA-85 (Croda Inc., Edison, NJ.), Incroquat WG-85 (Croda Inc., Edison, NJ.), as well as distearyldimonium chloride (e.g., VARISOFT® TA 100 (Essen-Degussa, Germany)), palmitamidopropyltrimonium chloride (e.g., VARISOFT® PATC (Essen- Degussa, Germany)), and cetearyl alcohol (and) palmitamidopropyltrimonium chloride (e.g., TEGO® Care CE 40).

In non-limiting embodiments of the invention, the amount of cationic emulsifier may be between about 0.2 and 1.0 percent and preferably between about 0.3 and 0.7 percent by weight of the cleansing composition.

NY02:ό2₅743.2 070050.3606

IR 2196, 2403 4.3 DISPERSING AUXILIARY SOLVENTS

Non-limiting examples of dispersing auxiliary solvents which may be used according to the invention include polyglycerols (e.g., diglycerol), polyglycerol esters, dipropylene glycol, tripropylene glycol, and tetrapropylene glycol. In non-limiting embodiments of the invention, the amount of dispersing auxiliary solvent may be between about 0.5 and 8.0 percent or between about 0.5 and 5.0 percent, by weight, of the cleansing composition.

4.4 NON-IONIC POLYMERS A "non-ionic polymer," as that term is used herein, is a compound which, in a cleanser composition, acts as a foaming agent or foam-stabilizing agent.

Non-limiting examples of non-ionic polymers which may be used according to the invention include polyethylene oxide (e.g., Polyox polymers, such as Polyox N 60K), and pluronic block copolymer surfactants (e.g., Pluronic F87 Prill. F127, F108, L43, and 25R8).

In non-limiting embodiments of the invention, the amount of non-ionic polymer may be between about 1 and 8 percent by weight of the cleansing composition.

4.5 SOLVENT SYSTEMS

Solvent systems according to the invention comprise water and an alcohol.

Non-limiting examples of alcohols which may be used according to the invention include ethanol, SDA-40B alcohol, SDA-3 C alcohol and butanol.

NY02 62₅74₃ 2 07 .3

IR 2196, 2403 In non-limiting embodiments, the amount of alcohol is between about

5 and 30 percent by weight of the cleansing composition.

4.6 ALKANEDIOLS In certain non-limiting embodiments, the present invention provides for compositions which comprise one or more alkanediol. Without being bound to any particular theory, it is believed that an alkanediol together with a cationic emulsifying agent forms a hydrophobic matrix on the skin upon application. Suitable alkanediols include, but are not limited to, dodecanediol, decanediol, nonanediol, octanediol, heptanediol, hexanediol and pentanediol. In particular non-limiting embodiments, the alkanediols have a carbon backbone of between 9 and 25 carbon atoms, including but not limited to 1,9 Nonanediol, 1,2-Decanediol, 1,10-Decanediol, 1,11-Undccanediol, 1 ,2-Dodecanediol, 1,12 Dodecanediol, Cyclododecanediol, 1,13- Tridecanediol, 1,2-Tetradecanediol,l,14-Tetradecanediol, 1,15-Pentadecanediol, 1,16- Hexadecanediol, 1,17-Heptadecanediol, 1,18-Octadecanediol, 1,19-Nonadecanediol, 1 ,20-Eicosanediol, 1,21-Heneicosanediol, 1,22-Docosanediol, 1,23-Tricosanediol, 1 ,24-Tetracosanediol, 1 ,25-Pentacosanediol.

4.7 CLEANSER COMPOSITIONS

The present invention provides for cleanser compositions comprising one or more cationic antiseptic agents, a cationic emulsifying agent, a dispersing auxiliary solvent, a solvent system, and optionally an alkanediol with preferred embodiments further comprising one or more non-ionic polymer; said composition optionally further comprising: one or more thickening agent, one or more film- forming agent, one or more emollient, one or more cationic or non-ionic surfactants, one or more auxiliary foaming agent, an auxiliary antimicrobial agent, one or more

NY02:ό2₅743.2 10 070050.3606

IR 2196, 2403 fragrance, etc., including combinations thereof. The compositions of the invention, in certain embodiments, comprise anti-irritant amounts of zinc salts; in other embodiments, the compositions of the invention do not comprise anti-irritant amounts of zinc salts. In preferred non-limiting examples of the invention, a cleanser composition comprises three cationic antiseptic agents. In specific non-limiting embodiments of the invention, the cleanser comprises chlorhexidine, a quaternary ammonium compound, and triclosan, and, optionally, phenoxyethanol, and preferably contains no additional antimicrobial agent that contains an aromatic ring structure.

Non-limiting examples of film-forming agents include cellulosic film- forming agents such as Ucare Polymer (e.g. , Polyquaternary 10), hydroxypropylmethyl cellulose (e.g., Methocel), and hydroxymethyl cellulose (e.g., Klucel), or a combination thereof. In specific non-limiting examples, the amount of cellulosic film-forming agent(s), where present, may be between about 0.05 and 0.5 percent by weight of the cleanser composition. Other examples of film-forming agents include silicone film-forming agents such as D.C.200, 556, 1403 and D. C. silicone wax 580.

Non-limiting examples of an emollient which may be used according to the invention include silicone polymers (e.g., Dow Corning Q2-5220), glycerin, phospholipid complex, octanediol, pentanediol, hexanediol, Petrolatum, and mixtures thereof. In specific, non-limiting embodiments, the amount of emollient(s), where present, may be between about 1 and 5 percent by weight of the cleanser composition and, for petrolatum, between about 0.5 and 3 percent by weight of the composition..

Non-limiting examples of auxiliary foaming agents which may be used according to the invention include quaternised foaming coconut oil (e.g., Montaline® C-40, Seppic Inc., Fairfϊeld, NJ.)), incromine oxide (e.g., Incromide oxide L),

NY02:62574₃ 2 1 1 070050.3606

IR 2196, 2403 cocamidopropyl betame or cocodimomum hydroxysultaine (e g , Crosultaine C-50)

In specific, non-limiting embodiments of the invention, the amount of surfactant/foaming agent(s), where present, may be between about 1 and 8 percent by weight of the cleanser composition. A non-limiting example of an auxiliary antimicrobial agent is 2- phenoxy-ethanol. In specific, non-limiting embodiments of the invention, the amount of 2-phenoxy-ethanol may be between about 0.5 and 2 percent, or about 1 percent, by weight of the cleanser composition

In particular non-hmitmg embodiments, the cleanser composition is a soap, which may be prepared as follows. Non-ionic polymer(s), water-soluble antiseptic agent(s), and cellulosic film-forming agent(s) (if any) may be mixed with water to form a first solution, which may be a gel (in a specific non-limiting embodiment, non-ionic polymer(s) and cellulosic film forming agent(s) may be mixed with water to form a gel to which water-soluble antiseptics are added) Auxiliary solvent and cationic emulsifying agent may then be mixed with alcohol and any alcohol-soluble antiseptic(s) or auxiliary antimicrobial agent may be added, to form a second solution The first and second solutions may then be mixed, and surfactants/foaming agents and emollients may be added.

One or more alkanediol may be incorporated into any of the foregoing compositions. In further, particular non-limiting embodiments, the invention provides for a skin disinfectant composition composing 1 ) one or more catiomc antiseptic agent, 2) a film-forming cationic emulsifying agent; 3) a dispersing auxiliary solvent; 4) an alkanediol, and 5) a solvent system compπsing an alcohol and water Said compositions may further contain a thickening and/or film forming agent such as cationic cellulose polymer, film forming silicone, emollients, and/or cationic or non-

NY02 625743 2 12 070050.3606

IR 2196, 2403 ionic surfactants/foaming agents. Non-limiting specific examples of dispersing auxiliary solvents which may be comprised in such compositions include 0.5 - 5 percent polyglycerol (w/w) (diglycerol) or diproopylene glycol. A non-limiting example of a film-forming emulsifier which may be comprised in such compositions is 0.3-1.0% behenyltrimonium methosulfate in cetearyl alcohol (Incroquat Behenyl TMS). Specific non-limiting examples of alkanediols which may be comprised in such compositions include but are not limited to C5-C14-containing compounds. Specific non-limiting examples of alcohols which may be comprised in such compositions include 5-20% w/w ethanol, SDA-40B alcohol and SDA-3 alcohol. Specific non-limiting examples of antimicrobial agents which may be comprised in such compositions include 0.2 - 1.0% w/w biguanide (e/.g. chlorhexidine and/or polyhexamethelene biguanide); 0.15-1 % w/w triclosan; 0.1-0.3 % w/w benzathonium chloride or benzalkonium chloride or a combination thereof. Specific non-limiting examples of film-forming cellulosic polymers which may be comprised in such compositions include 0.05-0.5% w/w UCare polymer (Polyquaternary 10); 0.05-0.5% w/w hydroxypropylmethyl cellulose (Methocel), or 0.05-0.5% w/w hydroxymethylcellulose (Klucel) or a combination thereof. Specific non-limiting examples of emollients which may be comprised in such compositions include a silicone polymer such as Dow Corning Q2-5220 (e.g. 0.5-3.0%), glycerin, and/or phospholipid complex. Non-limiting examples of surfactants/foaming agents which may be comprised in such compositions include 1-8% w/w quaternized foaming coconut oil (Montaline C40), 1-8% w/w incromine oxide, or 1-8% w/w cocoamidopropylbetaine. Non-limiting examples of film-forming silicones which may be comprised in such compositions include Dow Corning silicones 200, 556, 580 and/or 1403.

NY02:625743.2 13 070050.3606

IR 2196, 2403

Specific non-limiting embodiments of compositions according to the invention are provided below and in the example sections, and those provided in the example sections are incorporated into this section by reference.

Soaps containing Octanediol

Ingredients Percentage (w/w)

TCB-Z Soap TCB-Z-O Soap TCB-O Soap

Deionized Water 59.22 58.72 59.12

Zinc Lactate 0.2 0.2 -

Zinc gluconate 0.2 0.2 -

Pluronic F87 Prill 2.0 2.0 2.0

Polyox N-60K 0.2 0.2 0.2

U-care JR 30M 0.4 0.4 0.4

Montaline C-40 5.0 5.0 5.0

Incromide Oxide L 8.0 8.0 8.0

Crosultaine C-50 3.0 3.0 3.0

2-Phenoxyethanol 1.0 1.0 1.0

Diglycerol 2.0 2.0 2.0

SDA 4OB alcohol 15.0 15.0 15.0

Incroquat Behenyl TMS 0.3 0.3 0.3

1 , 2 Octanediol - 0.5 0.5

D-L Panthenol 50W 1.0 1.0 1.0

Phospholipid CDM 1.0 1.0 1.0

Chlorhexidine gluconate

(20% Solution) 1.0 1.0 1.0

Benzethonium Chloride 0.18 0.18 0.18

Triclosan 0.3 0.3 0.3

NY02 62574₃ 2 14 07 .

IR 2196, 2403

Soaps containing Pentanediol, and Symdiol (Hexanediol+ Octanediol)

Ingredient Percentage (w/w)

TCB-Z-P Soap TCB-Z-Svm Soap

Deionized Water 58.72 58.72

Zinc Lactate 0.2 -

Zinc gluconate 0.2 - Pluronic F87 Prill 2.0 2.0

Polyox N-60K 0.2 0.2

U-care JR 30M 0.4 0.4

Montaline C-40 5.0 5.0

Incromide Oxide L 8.0 8.0 Crosultaine C-50 3.0 3.0

2-Phenoxyethanol 1.0 1.0

Diglycerol 2.0 2.0

SDA 4OB alcohol 15.0 15.0

Incroquat Behenyl TMS 0.3 0.3 1,2 Pentanediol 0.5 -

Symdiol - 0.5

D, L Panthenol 50W 1.0 1.0

Phospholipid CDM 1.0 1.0

Chlorhexidine gluconate (20% solution ι)) 1.0 1.0 Benzethonium Chloride 0.18 0.18

Triclosan 0.3 0.3

NY02 6257« 2 15 U / 5 .

IR 2196, 2403 Soaps containing Decanediol and Dodecanediol

Ingredient Percentage (w/w)

TCB-Z- D Soap TCB-Z-Dod Soap

Deionized Water 58.72 59.12

Zinc Lactate 0.2

Zinc gluconate 0.2

Pluronic F87 Prill 2.0 2.0

Polyox N-60K 0.2 0.2

U-care JR 30M 0.4 0.4

Montaline C-40 5.0 5.0

Incromide Oxide L 8.0 8.0

Crosultaine C-50 3.0 3.0

2-Phenoxyethanol 1.0 1.0

Diglycerol 2.0 2.0

SDA 40B alcohol 15.0 15.0

Incroquat Behenyl TMS 0.3 0.3

1 ,2 Decanediol 0.5

1,12 Dodecanediol - 0.5

D, L Panthenol 50W 1.0 1.0

Phospholipid CDM 1.0 1.0

Chlorhexidine gluconate (20% solution) 1.0 1.0

Benzethonium Chloride 0.18 0.18

Triclosan 0.3 0.3

NY02 62574₃ 2 16 07 50.3

IR 2196, 2403

Foaming Cleanser with C5-C8 alkanediol (general formula)

Ingredient Percentaee

Water 50-65

Zinc Lactate 0.05-0.8

Zinc Gluconate 0.05-0.5

Pluronic F-87 1.0-5.0

Diglycerin 801 0.5-2.0

D,L Panthenol (50%) 0.5-1.0

Chlorhexidine/PHMB 0.05-1.0

Benzethonium Chloride 0.1-0.3

Lactic Acid (88%) 0.2-1.0

C5-C8 alkanediol 0.5-1.0

SDA 4OB alcohol 10-15

Incroquat Behenyl TMS 0.2-0.7

Triclosan 0.15-1.0

PHMB 0.1-0.3

Phenoxy ethanol 0.5-1.0

Montaline C-40 3-5

Incromine Oxide L 3-8.

Silicone D.C. 556 0-1

Solubilizer 611674 (Symrise) 0-2.0

Fragrance 0-1.5

FD&C Red 40 (.l%) 0-1.0

Total With water 100.0

NY02 6257432 17 070050.3606

IR 2196, 2403 In non-limiting embodiments, the present invention provides for the following topical formulations.

TCB-Z cream (Comprising Triclosan,Chlorhexidine, Benzathonium chloride and Zinc salts)

Ingredient Percentage (w/w)

Water 71.52

Ucare JR 40 0.3 Zinc gluconate 0.2

Zinc lactate 0.2

Zinc oxide 0.2

Polowax 3.0

Incroquat Behenyl TMS 3.0 Petroleum jelly 5.0

Stearyl alcohol 7.0

Propylene glycol 2.0

Isopropyl myristate 4.0

Sorbitan oleate 2.0 Polyoxyl 40 stearate 2.0

Triclosan 0.3

Chlorhexidine gluconate 0.2

Benzathonium Chloride 0.18

NY02:625743 2 1 8 070050.3606

IR 2196, 2403

TPB-Z cream

(Comprising Triclosan, PHMB, Benzathonium chloride and Zinc salts)

Ingredient Percentage (w/w) Water 72.02

Ucare JR 40 0.3

Polowax 3.0

Incroquat Behenyl TMS 3.0

Petroleum jelly 5.0 Stearyl alcohol 7.0

Propylene glycol 2.0

Isopropyl myristate 4.0

Sorbitan oleate 2.0

Polyoxyl 40 stearate 2.0 Triclosan 0.3

PHMB 0.3

Benzathonium Chloride 0.18

TPB-Z-P cream (Comprising Triclosan, PHMB, Benzathonium chloride Zinc salts and Pentanediol)

Ingredient Percentage (w/w)

Water 71.02

Zinc gluconate 0.2

Zinc lactate 0.2 Zinc oxide 0.2

NY02 625743 2 19 .

IR 2196, 2403

D, L Panthenol 0.5

Ucare JR 40 0.3

Polowax 3.0

Incroquat Behenyl TMS 3.0 Petroleum jelly 5.0

Stearyl alcohol 7.0

Propylene glycol 2.0

Isopropyl myri state 4.0

Sorbitan oleate 2.0 Polyoxyl 40 stearate 2.0

Triclosan 0.3

PHMB 0.3

Benzathonium Chloride 0.18

Pentanediol 0.5

FPBT-Z - cream

(Comprising Farnesol, PHMB, Benzathonium chloride, Triclosan, Zinc salts)

Ingredient Percentage (w/w) Water 70.92

Zinc gluconate 0.2

Zinc lactate 0.2

Zmc oxide 0.2

D, L Panthenol 0.5 Ucare JR 40 0.3

NY02 625743 2 20 U /0050.3606

IR 2196, 2403 Polowax 3.0

Incroquat Behenyl TMS 3.0

Petroleum jelly 5.0

Stearyl alcohol 7.0 Propylene glycol 2.0

Isopropyl myristate 4.0

Sorbitan oleate 2.0

Polyoxyl 40 stearate 2.0

Farnesol 0.5 PHMB 0.3

Benzathonium Chloride 0.18

Triclosan 0.3

FPBT-Z- P cream (Comprising Farnesol, PHMB, Benzathonium chloride, Triclosan,

Zinc salts and Pentanediol)

Ingredient Percentage (w/w)

Water 71.42

Zmc gluconate 0.2 Zinc lactate 0.2

Zinc oxide 0.2

D, L Panthenol 0.5

Ucare JR 40 0.3

Polowax 3.0 Incroquat Behenyl TMS 3.0

NY02 6257432 21 07 .

IR 2196, 2403

Petroleum jelly 5.0

Stearyl alcohol 7.0

Propylene glycol 2.0

Isopropyl myπstate 4.0 Sorbitan oleate 2.0

Polyoxyl 40 stearate 2.0

Farnesol 0.5

PHMB 0.3

Benzathonium Chloride 0.18 Triclosan 0.3

Pentanediol 0.5

FPBT-Z -O cream

(Comprising Farnesol, PHMB, Benzathonium chloride, Triclosan, Zinc salts and Octanediol)

Ingredient Percentage (w/w)

Water 70.92

Zinc gluconate 0.2 Zinc lactate 0.2

Zinc oxide 0.2

D, L Panthenol 0.5

Ucare JR 40 0.3

Polowax 3.0 Incroquat Behenyl TMS 3.0

Petroleum jelly 5.0

Stearyl alcohol 7.0

NY0262₅743 2 22 070050.3606

IR 2196, 2403

Propylene glycol 2.0

Isopropyl myristate 4.0

Sorbitan oleate 2.0

Polyoxyl 40 stearate 2.0 Farnesol 0.5

PHMB 0.3

Benzathonium Chloride 0.18

Triclosan 0.3

Octanediol 0.5

SFP-Z-O cream (Comprising Sensiva, Farnesol, PHMB, Zinc salts and octanediol)

Ingredient Percentage fw/w)

Water 67.4 Zinc gluconate 0.2

Zinc lactate 0.2

Zinc oxide 0.2

D, L Panthenol 0.5

Ucare JR 40 0.3 Polowax 3.0

Incroquat Behenyl TMS 3.0

Petroleum jelly 5.0

Stearyl alcohol 7.0

Propylene glycol 2.0 Isopropyl myristate 4.0

NY02:62574₃.2 23 IR 2196, 2403

Sorbitan oleate 2.0

Polyoxyl 40 stearate 2.0

Farnesol 0.5

Octoxyglyceπn( Sensiva) 2.0 PHMB 0.3

Phospholipid CDM 1.0 l, 2 Octanediol 0.5

SFPTr-Z-O cream (Comprising Sensiva, Farnesol, PHMB, Tea tree oil Zinc salts and Octanediol)

Ingredient Percentage (w/w)

Water 66.9

Zinc gluconate 0.2

Zinc lactate 0.2 Zinc oxide 0.2

D, L Panthenol 0.5

Ucare JR 40 0.3

Polowax 3.0

Incroquat Behenyl TMS 3.0 Petroleum jelly 5.0

Stearyl alcohol 7.0

Propylene glycol 2.0

Isopropyl myristate 4.0

Sorbitan oleate 2.0 Polyoxyl 40 stearate 2.0

NY026257432 24 , _r

U /0050 3606

IR 2196, 2403 Farnesol 0 5

Octoxyglyceπn( Sensiva) 2 0

PHMB 0 3 Phospholipid CDM 1 0 l, 2 Octanediol 0 5

Antibacterial anti-inflammatory cream (SFP-Z-O-AS)

(Comprising Sensiva, Farnesol ,PHMB, Zinc salts, Octanediol and the anti-inflammatory agent acetyl salicylic acid)

Ingredient Percentage (w/w)

Water 66 4

Zinc gluconate 0 2 Zmc lactate 0 2

Zinc oxide 0 2

Ucare JR 40 0 3

Polowax 3 0

Incroquat Behenyl TMS 3 0 Petroleum jelly 5 0

Stearyl alcohol 7 0

Propylene glycol 2 0

Isopropyl myπstate 4 0

Sorbitan oleate 2 0 Polyoxyl 40 stearate 2 0

Farnesol 0 5

NY02 625743 2 25 υ /0050.360

IR 2196, 2403 Octoxyglycerin( Sensiva) 2.0

Tea tree oil 0.5

PHMB 0.3

Phospholipid CDM 1.0 l,2 Octanediol 0.5

Acetyl salicylic acid 0.5

Antibacterial anti-inflammatory cream (SFP-Z-D-AS)

(Comprising Sensiva, Farnesol, PHMB, Zinc salts, decanediol and the antiinflammatory agent acetyl salicylic acid)

Ingredient Percentage (w/w)

Water 66.4

Zinc gluconate 0.2

Zinc lactate 0.2 Zinc oxide 0.2

Ucare JR 40 0.3

Polowax 3.0

Incroquat Behenyl TMS 3.0

Petroleum jelly 5.0 Stearyl alcohol 7.0

Propylene glycol 2.0

Isopropyl myristate 4.0

Sorbitan oleate 2.0

Polyoxyl 40 stearate 2.0 Farnesol 0.5

Octoxyglycerin( Sensiva) 2.0

Tea tree oil 0.5

NY02 62574₃2 26 U /0050.3606

IR 2196, 2403 PHMB 0.3

Phospholipid CDM 1.0

1 , 2 decaenediol 0.5

Acetyl salicylic acid 0.5

In specific non-limiting embodiments, the present invention provides for a hand disinfectant gel comprising an alkanediol, a cationic antiseptic agent, a film-forming cationic emulsifying agent, a dispersing auxiliary solvent and one or more essential oil for inactivating spores.

Healthcare Handwash with sporicidal agents HH-I

Constituent % (w/w) Panthenol 75W (BASF) 0.375

Zinc lactate 0.20

Benzethonium chloride 0.18

Symdiol 68T 1.0

Zinc gluconate 0.20 Farnesol 0.50

Cedar wood oil 0.5

Tea tree oil 0.5

Glucam P20 (Chemron) 0.50

Incroquat TMS Behenyl (Croda) 0.30 Methocell K4MS (Dow) 0.50

Polawax A31 (Croda) 0.50

Cosmocil CQ [PHMB (20% solution) 1.5

NY026257432 27 .

IR 2196, 2403

Phenoxyethanol 0.70 Alcohol (SDA-3C) 57.0 Sodium perborate 2.0 Water 33.6 Fragrance 50 μl

HH-2

Constituent % fw/w)

Panthenol 75W (BASF) 0.375 Zinc lactate 0.20

Benzethonium chloride 0.18

Symdiol 68T 1.0

Zinc gluconate 0.20

Farnesol 0.50 Cedar wood oil 0.5

Tea tree oil 0.5

Glucam P20 (Chemron) 0.50

Incroquat TMS Behenyl (Croda) 0.30

Methocell K4MS (Dow) 0.50 Polawax A31 (Croda) 0.50

Cosmocil CQ [PHMB (20% solution) 1.5

Phenoxyethanol 0.70

Alcohol (SDA-3C) 57.0

Peracetic acid 3.0 Water 32.6

Fragrance 50 μl

NY02:62₅743.2 28 U /0050.3606

IR 2196, 2403 4.8 METHODS OF USE

The cleanser compositions may be used to provide antimicrobial activity in methods comprising exposing a surface in need of such treatment to an effective amount of a cleanser composition as set forth above, for an effective period of time. An effective period of time may be at least about five seconds, at least about ten seconds, at least about twenty seconds, at least about thirty seconds, between thirty seconds and a minute, or between one minute and five minutes. In preferred non-limiting embodiments of the invention, antimicrobial activity is manifested as a logio reduction in bacteria of at least about 0.5, or at least about 1, or at least about 1.2, or at least about 1.5.

The cleanser compositions may be used to provide residual (persistent) antimicrobial activity in methods comprising exposing a surface in need of such treatment to an effective amount of a cleanser composition as set forth above, for an effective period of time. An effective period of time may be at least about five seconds, at least about ten seconds, at least about twenty seconds, at least about thirty seconds, between thirty seconds and a minute, or between one minute and five minutes. In preferred non-limiting embodiments of the invention, residual (persistent) antimicrobial activity is activity that persists for at least about 30 minutes.

The surface may be skin or mucous membrane of a human or non- human subject or may be a surface of an inanimate object, such as a telephone, a piece of medical examination equipment (e.g. a stethoscope or examination table), a piece of furniture, etc..

Accordingly, the cleansers of the invention may be used as topical skin cleansers, hand washes, personal washes, surgical scrubs, healthcare hand washes,

NY02 0257432 29 070050.3606

IR 2196, 2403 household cleaners, and the like. Optionally, a cleanser of the invention may be incorporated into a cleaning wipe.

5. EXAMPLE: SELECTION OF ANTISEPTIC AGENTS

Experiments were performed to evaluate the antimicrobial activity of combination of either l)Chlorhexidine gluconate( CHG), Triclosan ( TC)and Benzathonium chloride ( BZT), or

2) Polyhexamethylene biguanide ( PHMB), TC and BZT; relative to the antimicrobial activity of individual agents. The various antiseptics and combinations of antiseptics were incorporated in a soap base (Base C) as given in Table 1 . To 0.9 ml of the base, 0.1 ml of 108cfu/ml of S. aureus was added and mixed for one minute, after which 9.0 ml of drug inactivating media was added. The samples were mixed well and serial dilutions were made with drug inactivating media. Various dilutions were plated on TSA plates. As the control, 9.0 ml of soap base was used. The results are shown in Table 1.

Soap base C

Ingredient Percentage ( w/w)

Deionized Water 82.4 Polyox N 6OK 0.2

Pluronic F 87 Prill 2.0

U-care 0.4

Montaline c-40 8.0

Incromide Oxide L 3.0 Crosultaine C-50 3.0

2-Phenoxy-Ethanol 1.0

NY02 625743 2 30 070050.3606

IR 2196, 2403

TABLE 1

Antiseptics in base Colony counts Log 10 reduction from Control

Control 3.OxIO⁷

0.5% TC 4.3xlO⁶ 0.89

0.2% CHG 4.IxIO⁶ 0.92

0.3% PHMB 2.OxIO⁶ 1.17

0.18% BZT 3.9xlO⁶ 0.94

0.5% TC + 0 .2% CHG 1.OxIO⁶ 1.53

0.5% TC + 0 .2% CHG + 0.18% BZT 4.0 xlO' 2.9

0.5% TC + 0 .3% PHMB + 0.18^ζ s BZT 1 xlO⁴ 3.47

6. EXAMPLE: SOAP COMPOSITIONS

Soap Pl

Ingredient Percentage ( w/w) Deionized Water 71.82

Polyox N 6OK 0.2

Pluronic F 87 Prill 1.0.

Incromide Oxide L 3.0

Cocoamidopropylbetaine 1.0 2-Phenoxy-Ethanol 1.0

Di glycerol 5.0

Chlorhexidine gluconate (20% solution) 1.0

Benzethonium Chloride 0.18

SDA 4OB 15.0 Incroquat Behenyl TMS 0.3

NY026257432 31 υ / . IR 2196, 2403

Triclosan 0.5

Soap P-2 Ingredient Percentage ( w/w) Deionized Water 70.52

Zinc gluconate 0.2

Zinc lactate 0.1

Polyox N 6OK 0.2

Pluronic F 87 Prill 1.0. D,L Panthenol 5OW 1.0

Incromide Oxide L 3.0

Cocoamidopropylbetaine 1.0

2-Phenoxy-Ethanol 1.0

Diglycerol 5.0 Chlorhexidine gluconate (20% solution) 1.0

Soap P 3

Ingredient Percentage ( w/w)

Deionized Water 58.92 Polyox N 6OK 0.2

Pluronic F 87 Prill 2.0

U-care 0.4

Montaline c-40 8.0

Incromide Oxide L 3.0 Crosultaine C-50 3.0

2-Phenoxy-Ethanol 1.0

Diglycerol 3.0

NY02 625743 2 32 070050.3606

IR 2196, 2403

Q2-5220 Resin Modifier 0.5 Chlorhexidine gluconate (20% solution) 1.0

Benzethonium Chloride 0.18

SDA 4OB 15.0 Incroquat Behenyl TMS 0.3

Triclosan 0.5 l,2 Octanediol 1.0

CDM Phospholipid 2.0

Soap P-4

Ingredient Percentage (w/w)

Deionized Water 58.72

Methocel 40-202 0.2

Polyox N 6OK 0.2

Pluronic F 87 Prill 2.0

U-care 0.4

Montaline c-40 8.0

Incromide Oxide L 3.0

Crosultaine C- 50 3.0

2-Phenoxy-Ethanol 1.0

Diglycerol 3.0

Q2-5220 Resin Modifier 0.5

Chlorhexidine gluconate (20% solution) 1.0

Benzethonium Chloride 0.18

SDA 4OB 15.0

Incroquat Behenyl TMS 0.3

Triclosan 0.5

NY02 625743 2 33 070050.3606

IR 2196, 2403

1,2 Octanediol 1.0

CDM Phospholipid 2.0

Soap P 5

Ingredient Percentage (w/w)

Deionized Water 54.92

Zinc Lactate 0.2

Zinc gluconate 0.3

Polyox N 6OK 0.2

Pluronic F 87 Prill 2.0

U-care 0.4

Montaline C-40 7.0

Incromide Oxide L 7.0

2-Phenoxy-Ethanol 1.0

Diglycerol 5.0

D.C Q2-5220 Silicone 1.0

D-L Panthenol 5OW 1.0

Chlorhexidine gluconate (20% solution) 1.0

Benzethonium Chloride 0.18

SDA 4OB 15.0

Incroquat Behenyl TMS 0.3

Triclosan 0.5

1 ,2 Octanediol 1.0

CDM Phospholipid 2.0

NY02 625743 2 34 υ /0050.3606

IR 2196, 2403

Soap P6

Ingredient Percentage ( w/w)

Deionized Water 71.57 Polyox N 6OK 0.1

Ucare JR30 0.15

Pluronic F 87 Prill 1.0

Incromide Oxide L 1.0

Cocoamidopropylbutane 1.0 Farnesol 0.5

Diglycerol 5.0

Chlorhexidine gluconate (20% solution) 1.0

Benzethonium Chloride 0.18

SDA 4OB 15.0 Incroquat Behenyl TMS 0.5

Triclosan 0.5

Hydrolite 5( Pentanediol+hexanediol) 2.5

7. EXAMPLE: METHOD OF PREPARING A SOAP Polyox N 60 K and Pluronic F 87 surfactant and cellulose polymers such as Ucare JR 30 and Methocel are dissolved in water until a gel is formed( Gel A) and Chlorhexidine gluconate( CHG) and Benzathonium chloride(BZT) are mixed with GeIA. The auxiliary solvent Diglycerol is then added. Incroquat Behenyl TMS is dissolved in alcohol ( solution B) and triclosan and phenoxy ethanol are then mixed with solution B. solution B is added to Gel A and mixed thoroughly. To the A+B Gel mixture, surfactants/foaming agents and emollients are added.

NY02 625743 2 35 ^_rA , ^ υ /0050.3606 IR 2196, 2403

8. EXAMPLE: IN VITRO EVALUATION OF ACTIVITY

The antimicrobial efficacy of Soap Pl according to the invention (see Section 6) was evaluated using a modification of the FDA procedure (FDA MONOGRAPH PART IV 21 CFR PARTS 333 AND 369).

A fresh overnight culture of bacteria was prepared and diluted to obtain 10⁹ cfu organism/ml. 0.1ml of this diluted culture and 0.1 ml of Bovine Serum were introduced into a sterile culture tube. 0.8 ml of the soap formulation to be tested was added to the tube and then vortexed for 30 seconds. For the control, 0.9 ml of PBS (Phosphate buffered saline) was added to the tube containing the culture and processed the same way as the test soaps. Then, 9.0 ml of drug inactivating media was added to neutralize the activity of the soap, and the tube was vortexed. Serial dilutions were made using drug inactivating media. 0.5 ml from various dilutions were plated on Trypticase Soy agar plates.TSA plates). The plates were then incubated at 37°C for 24-48 hours, and then the colony counts were measured. The results are shown in Table 2.

TABLE 2

Organism Log 10 Reduction from control counts* S. epidermidis 4.458

S. aureus 2.1

MRSA 2.1

E. faecalis 4.18

VREF 4.83 Pseudomonas 8.53

Serratia 3.81

NY02:625743.2 36 _Λ

070050.3606

IR 2196, 2403

Acinetobacter 8.36 E. coli 8.52 Klebsiella 8.57 Enterobacter 3.81

* Control counts are 1-2x10⁸ cfu/ml

9. EXAMPLE: IN VIVO TESTING 1

This test was carried out to determine the residual antimicrobial remaining in the hand 5 minutes after washing the soap from the hand.

Trypticase agar plates were seeded with 3x10 cfu S aureus. Hands were washed with Soap P2 (see section 6), after donning a glove on the left hand (which served as the control). After washing, the glove was removed off the left hand. After allowing the hands to air dry for 5 minutes, the 3 middle fingers from both hands were pressed on the inoculated agar plate. One minute later, the same middle fingers of both hands were pressed onto two separate fresh (uninoculated) plates. After incubation at 37°C for 24 hours, the bacterial colonies in the plates were counted. The results are shown in Table 3.

TABLE 3

Control hand Test hand

CFU/Plate CFU/Plate

Volunteer 1 80 0

Volunteer 2 137 0

NY02:ό2₅743.2 37 _{ΛΛr Λ} υ /0050.3606 IR 2196, 2403

The results indicate that the hand washed with soap P2 showed retention of activity 5 minutes after washing.

10. EXAMPLE: IN VIVO TESTING 2 To test residual activity 30 minutes after washing with soap P3, hands were washed with water, dried, and a glove was donned on the left hand. 5 ml soap P3 was dispensed on the palm of the hand and was spread for 15 seconds, then a small amount of water was added to the palm and lathered for another 15 seconds. The hands were washed for 15 seconds and then rinsed and dried with paper towel. The glove was removed from the left hand. After 30 minutes the middle 3 fingers from both hands were pressed for 5 seconds on a TSA plate seeded with 0.3 ml of 10⁵ cfu S aureus/nύ . After 1 minute, the fingers were pressed on a sterile agar plate to see the transfer of bacteria from the hand to the plate. The gloved hand was used as the control. After incubation at 37°C for 24 hours the bacterial colonies on the plates were counted.

The results are shown in Table 4, below.

TABLE 4

Result Log 10 Counts LoglO reduction from the control Control 1.9

Soap P 3 0 1. 9

The foregoing data indicate that the hand washed with soap P 3 showed residual activity 30 minutes post washing.

NY02 62₅743.2 38 IR 2196, 2403 11. EXAMPLE: COMPARISON WITH COMMERCIAL PRODUCT

To compare the efficacy of soap P5 (see Section 6) with commercially available Dial Complete® (which contains 0 46 percent tπclosan), essentially the same method set forth in section 10 was used, except that after pressing the hands on plates seeded with bacteria, they were pressed on drug inactivating agar. The test plates were incubated at 37°C for 24 hours. The results are presented in Table 5.

TABLE 5

Log 10 Counts LoglO reduction from the control Control 1 0

Dial Complete® (0.46% Triclosan) 1 19 -0.19

Soap P5 0.3 0.7

The results shown in Table 5 indicate that 30 minutes after washing, the hand washed with Soap P5 a exhibited superior antimicrobial activity relative to Dial Complete.

12. EXAMPLE: EFFICACY TESTING ON PIG SKIN

In these experiments, the residual antimicrobial activity of Soap P6 (see Section 6) was compared to Soap 30, having the following formulation.

NY02 6257432 39 07 .

IR 2196, 2403

Composition of Soap 30 Ingredient Percentage (w/w)

Deionized Water 71.82

Zinc gluconate

0.1

Pluronic F 87 Prill 1.0

Polyox N-60K 0.2

U-care 0.4 Germal+ 0.15

Montaline C-40 3.0

Incromide Oxide L 3.0

2-Phenoxy-Ethanol 1.0

Glycerin 2.0 SDA40 B alcohol 14

D-L Panthenol 50W 1.0

Chlorhexidine gluconate 0.2

Benzethonium Chloride 0.18

PHMB 0.30 Farnesol 0.3

Triclosan 0

Two sets of pigskins were used for each group. Control skins were washed with non-antimicrobial soap and the test skins were washed with either soap P6 or soap 30, with 20 seconds of lathering

NY02:625743.2 40 _^^ „ ,_n υ/0050.360

IR 2196, 2403 followed by 20 seconds of rinsing. After washing, the pig skins were dried and left at room temperature for 30 minutes .

Then, each skin was inoculated with lOul of 10⁵ cfu/ml S aureus, which was spread on the skin for 30 seconds and then allowed to remain for another 30 seconds, after which 0.2 ml of drug inactivating media was applied and rubbed onto the skin for 15 seconds. The skins were then washed with 9.9 ml of drug inactivating media, and the washings were collected. Serial dilutions of the washings were made and plated on TSA plates. After incubating 24 hours at 37°C the colony counts were determined. The results are shown in Table 6.

TABLE 6

Log 10 Counts LoglO reduction from the control Control* 2.36

Control** 3.29 0.07 Soap 30 3.2 0.16

Soap P6 2.17 1.19

* no soap used

** regular (non-antimicrobial) soap used

The results indicate that Soap P6 had greater residual activity after 30 minutes than non-antibacterial soap or soap 30.

NY02:625743.2 41 070050.3606

IR 2196, 2403

13. EXAMPLE: COMPARISON TESTING

The following study compared the persistence of antimicrobial activity of soaps having the same concentrations of cationic antiseptics, but where soap ClO lacked the auxiliary solvent diglycerol and the cationic emulsifier Incroquat TMS.

Ingredient Percenta§ ξe(w/w) Soap PC2-5A Cl O

Deionized Water 62.97 66.3 Zinc Lactate 0.1 0.1

Zinc gluconate 0.1 0.1

Pluronic F 87 Pπll 1.0 1.0

U-care 0.2 0.2

Montaline C-40 5.0 5.0 Incromide Oxide L 7.0 7.0

2-Phenoxy-Ethanol 1.0 1.0

Diglycerol 5.0 -

SDA40 B alcohol 15 15

Incroquat TMS 0.3 - D-L Panthenol 50W 1.0 1.0

Chlorhexidine gluconate (20% solution) 1.0 1.0

Benzethonium Chloride 0.23 0.23

PHMB 0.30 0.3

Triclosan 0.5 0.5

Two pigskins were used as controls, two pigskins were used to test

PC2-5A soap and two pigskins were used to test ClO soap. After washing a pigskin

NY02 62₅743 2 42 070050.3606

IR 2196, 2403 with soap, it was air dried and left at room temperature for 2 hours. Then, each skin was pressed on an inoculated agar plate for 5 seconds, left at room temperature for 1 minute, and then pressed on a drug inactivating agar plate. The plates were incubated at 37°C for 24 hours and colony counts were determined. Log reductions for the counts were calculated, and are shown in Table 7.

TABLE 7

Log Reduction

LoglO Counts from the control counts

Control 1.90 —

Soap ClO 1.0 0.9

Soap PC25A 0.12 1.78

The results indicate that the soap having auxiliary dispersing solvent and cationic emulsifier displayed greater persistent antimicrobial activity.

14. EXAMPLE: ALKANEDIOL CONTAINING SOAPS

Cleansing compositions were prepared containing alkanediols with carbon C5-C12, cationic antiseptic agents, a film-forming cationic emulsifying agent, a dispersing auxiliary solvent. In particular, soaps containing the following alkanediols were prepared: Pentanediol , Hexanediol + Octanediol (Symdiol), Octanediol, Decanediol, Dodecanediol were used in the following cleansing formulations.

Soaps containing Octanediol Ingredients Percentage (w/w)

TCB-Z Soap TCB-Z-O Soap TCB-O Soap

Deionized Water 59.22 58.72 59.12

NY02:625743.2 43 070050.3606 IR 2196, 2403

Zmc Lactate 0 2 0 2 -

Zinc gluconate 0.2 0 2 -

Pluronic F87 Prill 2.0 2.0 2 0

Polyox N-60K 0.2 0.2 0.2

U-care JR 30M 0.4 0.4 0.4

Montaline C-40 5.0 5.0 5.0

Incromide Oxide L 8 0 8.0 8.0

Crosultaine C- 50 3 0 3.0 3 0

2-Phenoxyethanol 1 0 1.0 1 0

Diglycerol 2 0 2.0 2 0

SDA 4OB alcohol 15.0 15.0 15.0

Incroquat Behenyl TMS 0.3 0.3 0.3

1 , 2 Octanediol - 0.5 0.5

D-L Panthenol 50W 1.0 1.0 1.0

Phospholipid CDM 1.0 1.0 1.0

Chlorhexidine gluconate

(20% Solution) 1.0 1 0 1.0

Benzethonmm Chloride 0.18 0 18 0 18

Tπclosan 0.3 0.3 0 3

Soaps containing Pentanediol, and Symdiol (HexanedioH- Octanediol)

Ingredient Percentage (w/w)

TCB-Z-P Soap TCB-Z-Sym Soap

Deiomzed Water 58.72 58.72 Zmc Lactate 0.2

NY02 625743 2 44 U /0050.3

IR 2196, 2403

Zinc gluconate 0.2 -

Pluronic F87 Prill 2.0 2.0

Polyox N-60K 0.2 0.2

U-care JR 30M 0.4 0.4

Montaline C-40 5.0 5.0

Incromide Oxide L 8.0 8.0

Crosultaine C-50 3.0 3.0

2-Phenoxyethanol 1.0 1.0

Diglycerol 2.0 2.0

SDA 4OB alcohol 15.0 15.0

Incroquat Behenyl TMS 0.3 0.3 l,2 Pentanediol 0.5 -

Symdiol - 0.5

D, L Panthenol 50W 1.0 1.0

Phospholipid CDM 1.0 1.0

Chlorhexidine gluconate (20% solution) 1.0 1.0

Benzethonium Chloride 0.18 0.18

Triclosan 0.3 0.3

Soaps containing Decanediol and Dodecanediol

Ingredient Percentage (w/w)

TCB-Z- D Soap TCB-Z-Dod Soap

Deionized Water 58.72 59.12

Zinc Lactate 0.2 -

Zinc gluconate 0.2 -

Pluronic F87 Prill 2.0 2.0

Polyox N-60K 0.2 0.2

U-care JR 30M 0.4 0.4

NY02 ό2S74₃ 2 45 IR 2196, 2403

Montaline C-40 5.0 5.0

Incromide Oxide L 8.0 8.0

Crosultaine C-50 3.0 3.0

2-Phenoxyethanol 1.0 1.0 Diglycerol 2.0 2.0

SDA 40B alcohol 15.0 15.0

Incroquat Behenyl TMS 0.3 0.3

1 ,2 Decanediol 0.5

1,12 Dodecanediol - 0.5 D, L Panthenol 50W 1.0 1.0

Phospholipid CDM 1.0 1.0

Chlorhexidine gluconate (20% solution) 1.0 1.0

Benzethonium Chloride 0.18 0.18

Triclosan 0.3 0.3

Foaming Cleanser with C5-C8 alkanediol (general formula)

Ingredient Percentage Water 50-65

Zinc Lactate 0.05-0.8

Zinc Gluconate 0.05-0.5

Pluronic F-87 1.0-5.0

Diglycerin 801 0.5-2.0 D,L Panthenol (50%) 0.5-1.0

Chlorhexidine/PHMB 0.05-1.0

Benzethonium Chloride 0.1-0.3

Lactic Acid (88%) 0.2-1.0

NY02:625743.2 46 υ / . IR 2196, 2403

C5-C8 alkanediol 0.5-1.0

SDA 40B alcohol 10-15

Incroquat Behenyl TMS 0.2-0.7

Triclosan 0.15-1.0 PHMB 0.1-0.3

Phenoxy ethanol 0.5-1.0

Montaline C-40 3-5

Incromine Oxide L 3-8.

Silicone D.C. 556 0-1 Solubilizer 611674 (Symrise) 0-2.0

Fragrance 0-1.5

FD&C Red 40 (.l%) 0-1.0

Total With water 100.0

Some of the foregoing soaps were then tested for antimicrobial activity. Four sets of pigskins were used for each group. Control skins were washed with non-antimicrobial soap (Plain soft soap) and the test skins were washed with test soaps (20 seconds lathering and 20 seconds rinsing). After washing, the pig skins were dried and left at room temperature for 60 minutes. The skins were pressed for 5 seconds on a pre inoculated Trypticase soy agar plate, inoculated with 0.5 ml of 10⁴ cfu/ml oϊS.aureus. After 1 minute, each skin was rinsed with 10 ml drug inactivating media and the washings were collected. Serial dilutions of the washings were made and plated on TSA plates. After incubating 24 hours at 37°C the colony counts were determined. The results are shown in Table 8.

NY02:625743.2 47 IR 2196, 2403

Table 8

Soap Groups Lo si 0 reduction from the control TCB-Z O .64 TCB-Z-O 1 .0

TCB-O 1. .02 TCB-Z-P 1 .30 TCB-Z-Sym 1 .29 TCB-Z - D 1.56 TCB-Z Dod 1 .38

Bacterial growth in the Pig skin washed with Control soap ranged from 2x10² to 8x10²

15. EXAMPLE: EFFECT OF FILM-FORMING SILICONES Soaps were prepared containing cationic antiseptic agents, a film- forming cationic emulsifying agent, a dispersing auxiliary solvent, an alkanediol and a film forming silicone. Dow Corning cosmetic grade 556 silicone fluid was used; 0.5% of the silicone fluid was used in TCB, TCB-Z-P and TCB-Z-O and the efficacy was evaluated using the pigskin method descnbed in Section 14. The results are shown in Table 9.

Table 9

Soap Groups LoglO reduction from the control

TCB-Z -O 1.0

NY02 6257432 48 IR 2196, 2403 TCB-Z-O-S 1.5

TCB-Z-P 1.29

TCB-Z-P-S 1.53

Bacterial growth in the Pig skin washed with Control soap ranges from 2x10 to 8x10²

These results indicate that the film forming silicon further enhances persistent antimicrobial activity.

16. EXAMPLE: TOPICAL CREAMS It has been shown that healthcare workers play a major role in MRSA transmission, they become colonized or infected with MRSA from patients, but also can infect them and even become the MRSA carriers. Various topical creams (see Section 4.7 for formulations) were evaluated for their activity against MRSA infection using a pig skin model. Six sets of 3x3cm² Pig skin each mounted on a petri plate were rinsed in 70% Ethanol, and air dried; one piece of the pair was contaminated with 30μl of 10⁸ cfu of MRSA culture; the two pieces were rubbed against each other for 30 seconds , and left at 37⁰C dry for 1 hour. Three pairs were used for control and the other 3 pairs were used for the test creams. To one piece of the pair from the control, 0.1 gm of placebo cream (without the antibacterials) was applied, and rubbed against the other piece for 15 seconds and left at 37⁰C for 2 hours. The same procedure was repeated with the skins in which the test cream was applied. Following this, 0.2 ml drug inactivating media (DM) was added to one skin piece and both pieces rubbed again for 15 seconds. The surviving organisms were recovered from the skin by rinsing each piece with 9.9 ml of DM. The washing fluid from both pieces was

NY02:625743.2 49 υ / .

IR 2196, 2403 collected in one Petri dish, mixed and transferred to a culture tube from which further serial dilutions were made. Aliquots from the dilutions were plated on TSA plates and incubated for 24-48 hours at 37⁰C before colony counts (baseline counts) were determined.

Reduction of Bacterial growth 2 hour post treatment

Table 10 Treatment cream Logio reduction from control counts

Placebo cream (control) FPBT-Z 3.14

FPBT-Z-O 4.94

SFP-Tr-Z-AS 3.2

SFP-Tr-Z-O-AS 4.56

Bacterial growth in the Pig skin washed with Control soap ranges from 5x10⁶ to IxIO⁷

These results indicate that Alkanediols enhance the activity of creams containing antibacterials.

Various publications are cited herein, the contents of which are hereby incorporated by reference in their entireties.

NY02:625743.2 50

Claims

IR 2196, 2403 WE CLAIM-

1 A cleanser composition comprising one or more cationic antiseptic agent, a cationic emulsifying agent, a dispersing auxiliary solvent, and a solvent system, which demonstrates residual antimicrobial activity

2. The cleanser composition of claim 1, further comprising an alkanediol.

3 The cleanser composition of claim 1 or 2, further comprising one or more non-ionic polymer

4 The cleanser of claim 1 or 2, comprising the cationic antiseptic agent chlorhexidme.

5. The cleanser of claim 4, further comprising the cationic antiseptic agent tπclosan.

6 The cleanser of claim 4, further compπsing the cationic antiseptic agent, a quaternary ammonium compound

7. The cleanser of claim 5, further compπsing the cationic antiseptic agent, a quaternary ammonium compound

8. The cleanser of any of claims 1 -7, wherein the cationic emulsifying agent is an incroquat compound.

9. The cleanser of any of claims 1 -7, wherein the dispersing auxiliary solvent is selected from the group consisting of polyglycerols, polyglycerol esters, dipropylene glycol, tπpropylene glycol, and tetrapropylene glycol.

10. The cleanser of claim 9, wherein the polyglycerol is diglycerol.

11. A method of providing antimicrobial activity to a surface, compπsing exposing a surface in need of such treatment to an effective amount of a cleanser composition as set forth m any of claims 1-10, for an effective peπod of time.

NY02 6257432 51